Navigation Links
Monoclonal Antibody Partnering Terms & Agreements Discussed in New Report Now Available at MarketPublishers.com
Date:12/12/2012

London, UK (PRWEB) December 12, 2012

Monoclonal antibodies (mAb) represent one of the fastest growing segments of the global pharmaceutical market. In 2010, mAb market revenues amounted to more than USD 42.5 billion. Amgen Inc, Johnson & Johnson, Novartis AG, Eli Lilly and Company Biogen Idec, Merck & Co Inc, Abbott Laboratories and Roche Holding Ltd. are amid leading companies on the mAb market. The U.S. and Japan are the most prominent country markets for mAb.

New research report “Monoclonal Antibody Partnering Terms and Agreements” elaborated by CurrentPartnering has been recently published by Market Publishers Ltd.

Report Details:

Title: Monoclonal Antibody Partnering Terms and Agreements
Published: December, 2012
Pages: 1252
Price:    US$ 2,695.00
http://marketpublishers.com/report/life_sciences/biotechnology/monoclonal-antibody-partnering-terms-n-agreements.html

The report delves into the monoclonal antibody market and reviews partnering deals and agreements in 2007-2012. The research study provides an extensive analysis of the mAb dealmaking directory by deal type, stage of development and by therapy indicators. Besides, the report thoroughly examines monoclonal antibody deals by technology type. The report offers comprehensive assessment of partnering deals and points out key market trends. It also indicates top companies active in the market and includes bigpharma monoclonal antibody partnering company profiles. Moreover, the research contains contract documents, deals’ records and their financial terms.

Reasons to Buy:

  •     The report offers a detailed overview of the global monoclonal antibodies market.
  •     The research study provides an in-depth understanding of trends of the monoclonal antibody market. It also unveils valuable data on partnering in the research, development and commercialization of biomarker technologies and products.
  •     The extensive analysis of the changing nature of deals terms provides an insight into the negotiation process and shows what one can expect to achieve during the negotiation of terms.
  •     The reports will help you to find answers to numerous questions about a prospective partner’s flexibility on a raft of important issues

More new market research reports and databases by the publisher can be found at CurrentPartnering page.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10230559.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
2. GeneTex Launches New Antibody Against Phosphorylated Histone H3 for Epigenetics Research
3. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
4. Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
5. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
6. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
7. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
8. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
9. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
10. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
11. AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
Breaking Biology Technology:
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):